688222 成都先导
已收盘 01-08 15:00:01
资讯
新帖
简况
每周股票复盘：成都先导（688222）员工持股计划完成非交易过户
证券之星 · 2025-12-28
每周股票复盘：成都先导（688222）员工持股计划完成非交易过户
成都先导药物开发股份有限公司宣布两大募投项目延期至2028年
中金财经 · 2025-12-27
成都先导药物开发股份有限公司宣布两大募投项目延期至2028年
成都先导宣布两大募投项目延期至2028年
中金财经 · 2025-12-27
成都先导宣布两大募投项目延期至2028年
成都先导（688222）披露2025年员工持股计划完成非交易过户，12月26日股价下跌1.15%
证券之星 · 2025-12-26
成都先导（688222）披露2025年员工持股计划完成非交易过户，12月26日股价下跌1.15%
成都先导(688222.SH)：蓉创先导基金拟4000万元增资摩熵智能取得51%股权
智通财经 · 2025-12-19
成都先导(688222.SH)：蓉创先导基金拟4000万元增资摩熵智能取得51%股权
12月19日成都先导涨8.31%，华泰柏瑞中证2000ETF基金重仓该股
证券之星 · 2025-12-19
12月19日成都先导涨8.31%，华泰柏瑞中证2000ETF基金重仓该股
成都先导（688222）披露股东减持股份结果公告，11月24日股价上涨6.61%
证券之星 · 2025-11-24
成都先导（688222）披露股东减持股份结果公告，11月24日股价上涨6.61%
11月24日成都先导发布公告，股东减持200万股
证券之星 · 2025-11-24
11月24日成都先导发布公告，股东减持200万股
每周股票复盘：成都先导（688222）将召开Q3业绩说明会
证券之星 · 2025-11-16
每周股票复盘：成都先导（688222）将召开Q3业绩说明会
成都先导（688222）披露拟申请注册发行债务融资工具，11月14日股价上涨2.3%
证券之星 · 2025-11-14
成都先导（688222）披露拟申请注册发行债务融资工具，11月14日股价上涨2.3%
成都先导（688222）披露召开2025年第三季度业绩说明会公告，11月10日股价下跌0.17%
证券之星 · 2025-11-10
成都先导（688222）披露召开2025年第三季度业绩说明会公告，11月10日股价下跌0.17%
每周股票复盘：成都先导（688222）股东减持185.94万股，股价上涨12.96%
证券之星 · 2025-11-09
每周股票复盘：成都先导（688222）股东减持185.94万股，股价上涨12.96%
11月7日成都先导发布公告，股东减持185.94万股
证券之星 · 2025-11-07
11月7日成都先导发布公告，股东减持185.94万股
【机构调研记录】红塔红土调研成都先导
证券之星 · 2025-11-03
【机构调研记录】红塔红土调研成都先导
每周股票复盘：成都先导（688222）Q3净利增114.98%
证券之星 · 2025-11-02
每周股票复盘：成都先导（688222）Q3净利增114.98%
成都先导(688222)9月30日股东户数2.07万户，较上期增加13.63%
证券之星 · 2025-10-29
成都先导(688222)9月30日股东户数2.07万户，较上期增加13.63%
成都先导：选举第三届董事会职工代表董事
证券日报网 · 2025-09-15
成都先导：选举第三届董事会职工代表董事
成都先导合作伙伴Bioage Labs启动新型脑渗透性Nlrp3抑制剂Bge-102的1期临床试验
美股速递 · 2025-09-15
成都先导合作伙伴Bioage Labs启动新型脑渗透性Nlrp3抑制剂Bge-102的1期临床试验
成都先导：合作伙伴BioAge启动新颖NLRP3抑制剂BGE-102的I期临床研究
格隆汇 · 2025-09-15
成都先导：合作伙伴BioAge启动新颖NLRP3抑制剂BGE-102的I期临床研究
每周股票复盘：成都先导（688222）2025年限制性股票激励对象公示无异议
证券之星 · 2025-09-14
每周股票复盘：成都先导（688222）2025年限制性股票激励对象公示无异议
加载更多
公司概况
公司名称：
成都先导药物开发股份有限公司
所属行业：
研究和试验发展
上市日期：
2020-04-16
主营业务：
成都先导药物开发股份有限公司的主营业务是DEL技术相关的药物研发服务。公司的主要产品是小分子及核酸新药。
发行价格：
20.52
{"stockData":{"symbol":"688222","market":"SH","secType":"STK","nameCN":"成都先导","latestPrice":30.75,"timestamp":1767855601000,"preClose":30.44,"halted":0,"volume":28073844,"delay":0,"changeRate":0.0102,"floatShares":401000000,"shares":401000000,"eps":0.2848,"marketStatus":"已收盘","change":0.31,"latestTime":"01-08 15:00:01","open":30.04,"high":31.39,"low":29.89,"amount":858000000,"amplitude":0.0493,"askPrice":30.77,"askSize":72,"bidPrice":30.75,"bidSize":41,"shortable":0,"etf":0,"ttmEps":0.2848,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767922200000},"marketStatusCode":5,"adr":0,"adjPreClose":30.44,"symbolType":"stock_kcb","openAndCloseTimeList":[[1767835800000,1767843000000],[1767848400000,1767855600000]],"highLimit":33.48,"lowLimit":27.4,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":400680000,"isCdr":false,"pbRate":8.38,"roa":"--","peRate":107.970506,"roe":"6.47%","epsLYR":0.13,"committee":-0.833231,"marketValue":12321000000,"turnoverRate":0.0701,"status":0,"afterMarket":{"amount":0,"volume":0,"close":30.75,"buyVolume":0,"sellVolume":0,"time":1767857637558,"indexStatus":"已收盘 01-08 15:30:00","preClose":30.44},"floatMarketCap":12321000000},"requestUrl":"/m/hq/s/688222","defaultTab":"news","newsList":[{"id":"2594224431","title":"每周股票复盘：成都先导（688222）员工持股计划完成非交易过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2594224431","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594224431?lang=zh_cn&edition=full","pubTime":"2025-12-28 02:28","pubTimestamp":1766860093,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，成都先导报收于23.97元，较上周的24.37元下跌1.64%。本周，成都先导12月24日盘中最高价报24.63元。公司公告汇总成都先导于2025年12月25日将回购专用证券账户中123.87万股公司股票非交易过户至“2025年员工持股计划”账户，过户价格为11.66元/股。本次员工持股计划共有107人参与，对应股份占公司总股本的0.31%，存续期为48个月，标的股票分两期解锁，每期解锁50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122800000455.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2594109262","title":"成都先导药物开发股份有限公司宣布两大募投项目延期至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=2594109262","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594109262?lang=zh_cn&edition=full","pubTime":"2025-12-27 15:40","pubTimestamp":1766821220,"startTime":"0","endTime":"0","summary":"中访网数据 成都先导药物开发股份有限公司于近日发布公告，宣布对其首次公开发行股票募集资金投资的两个主要项目进行延期。根据公司第三届董事会第四次会议审议通过的议案，“新分子设计、构建与应用平台建设项目”和“新药研发中心建设项目”达到预定可使用状态的日期，将从原计划的2025年12月延期至2028年3月。保荐机构中国国际金融股份有限公司经核查后，对本次募投项目延期事项无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251227/31896469.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0216","688222"],"gpt_icon":0},{"id":"2594210189","title":"成都先导宣布两大募投项目延期至2028年","url":"https://stock-news.laohu8.com/highlight/detail?id=2594210189","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594210189?lang=zh_cn&edition=full","pubTime":"2025-12-27 15:40","pubTimestamp":1766821218,"startTime":"0","endTime":"0","summary":"中访网数据 成都先导药物开发股份有限公司于2025年12月25日召开董事会，审议通过了关于募集资金投资项目延期的议案。公司决定将“新分子设计、构建与应用平台建设项目”和“新药研发中心建设项目”达到预定可使用状态的日期，从原计划的2025年12月延期至2028年3月。此次延期不涉及项目实施主体、方式、用途及投资规模的变更。公司认为，本次延期不会对募投项目实施造成实质性影响，亦不存在变相改变募集资金投向或损害股东利益的情形。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251227/31896465.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2594294398","title":"成都先导（688222）披露2025年员工持股计划完成非交易过户，12月26日股价下跌1.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594294398","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594294398?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:19","pubTimestamp":1766758763,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，成都先导报收于23.97元，较前一交易日下跌1.15%，最新总市值为96.04亿元。本次员工持股计划实际参与认购员工共107人，最终认购份额为1,444.3242万份，对应股份数量为123.87万股，占公司总股本的0.31%。本次员工持股计划存续期为48个月，自最后一笔标的股票过户至本次员工持股计划名下之日起算，标的股票分两期解锁，每期解锁比例均为50%，具体解锁比例和数量根据公司层面业绩考核及持有人年度绩效考核结果确定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036268.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2592716386","title":"成都先导(688222.SH)：蓉创先导基金拟4000万元增资摩熵智能取得51%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2592716386","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592716386?lang=zh_cn&edition=full","pubTime":"2025-12-19 18:18","pubTimestamp":1766139497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，成都先导 发布公告，公司参与设立的蓉创先导基金将以自有资金进行增资的方式投资摩熵智能技术(成都)有限公司4000万元。蓉创先导基金中，成都先导作为有限合伙人，出资比例为40%，根据基金合伙协议及其附属协议，该基金纳入成都先导的合并报表范围。增资完成后，蓉创先导基金将取得目标公司51%的股权，目标公司将纳入成都先导合并报表范围。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383800.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"成都先导(688222.SH)：蓉创先导基金拟4000万元增资摩熵智能取得51%股权","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","688222"],"gpt_icon":0},{"id":"2592156203","title":"12月19日成都先导涨8.31%，华泰柏瑞中证2000ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2592156203","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592156203?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:33","pubTimestamp":1766129592,"startTime":"0","endTime":"0","summary":"证券之星消息，12月19日成都先导涨8.31%，收盘报24.37元，换手率5.19%，成交量20.8万手，成交额5.06亿元。重仓成都先导的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为华泰柏瑞基金的华泰柏瑞中证2000ETF。华泰柏瑞中证2000ETF目前规模为21.68亿元，最新净值1.3066，较上一交易日上涨0.05%，近一年上涨20.55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121900017663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["562660","BK0216","688222"],"gpt_icon":0},{"id":"2585460722","title":"成都先导（688222）披露股东减持股份结果公告，11月24日股价上涨6.61%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585460722","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585460722?lang=zh_cn&edition=full","pubTime":"2025-11-24 22:14","pubTimestamp":1763993667,"startTime":"0","endTime":"0","summary":"截至2025年11月24日收盘，成都先导报收于22.9元，较前一交易日上涨6.61%，最新总市值为91.76亿元。近日，成都先导发布股东拉萨经济技术开发区华博医疗器械有限公司减持股份结果公告。公告显示，本次减持计划实施前，华博器械持有公司股份44,770,579股，占总股本的11.17%。2025年8月5日，公司披露减持计划，华博器械拟通过集中竞价方式减持不超过3,000,000股，占总股本约0.75%，减持期间为2025年8月26日至11月25日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400035389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2585246380","title":"11月24日成都先导发布公告，股东减持200万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2585246380","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585246380?lang=zh_cn&edition=full","pubTime":"2025-11-24 18:03","pubTimestamp":1763978585,"startTime":"0","endTime":"0","summary":"证券之星消息，11月24日成都先导发布公告《成都先导:成都先导药物开发股份有限公司股东拉萨经济技术开发区华博医疗器械有限公司减持股份结果公告》，其股东拉萨经济技术开发区华博医疗器械有限公司于2025年9月4日至2025年11月24日间合计减持200.0万股，占公司目前总股本的0.4992%，变动期间该股股价下跌20.49%，截止11月24日收盘报22.9元。股东增减持详情见下表：根据成都先导2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112400023749.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2583651647","title":"每周股票复盘：成都先导（688222）将召开Q3业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651647","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651647?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:33","pubTimestamp":1763235191,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，成都先导报收于24.45元，较上周的23.23元上涨5.25%。本周，成都先导11月14日盘中最高价报24.99元。本周关注点公司公告汇总：成都先导将于2025年11月25日召开第三季度业绩说明会。公司公告汇总成都先导药物开发股份有限公司将于2025年11月25日11:00-12:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司当季经营成果及财务状况。成都先导于2025年11月14日召开第二次临时股东会，审议通过上述债务融资工具发行议案。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000862.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2583502430","title":"成都先导（688222）披露拟申请注册发行债务融资工具，11月14日股价上涨2.3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2583502430","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583502430?lang=zh_cn&edition=full","pubTime":"2025-11-14 22:36","pubTimestamp":1763130988,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，成都先导报收于24.45元，较前一交易日上涨2.3%，最新总市值为97.97亿元。近日，成都先导发布2025年第二次临时股东会决议公告，公司于2025年11月14日召开临时股东会，审议通过了关于拟申请注册发行银行间债券市场非金融企业债务融资工具的议案。北京君合（成都）律师事务所对本次会议进行了见证，并出具法律意见书，认为会议的召集、召开程序、出席人员资格、表决程序及表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400041963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688222"],"gpt_icon":0},{"id":"2582877847","title":"成都先导（688222）披露召开2025年第三季度业绩说明会公告，11月10日股价下跌0.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582877847","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582877847?lang=zh_cn&edition=full","pubTime":"2025-11-10 22:20","pubTimestamp":1762784443,"startTime":"0","endTime":"0","summary":"截至2025年11月10日收盘，成都先导报收于23.19元，较前一交易日下跌0.17%，最新总市值为92.92亿元。公司近日发布公告称，将于2025年11月25日11:00-12:00通过上证路演中心网络互动方式召开2025年第三季度业绩说明会，介绍公司2025年第三季度经营成果及财务状况。投资者可于11月18日至24日通过上证路演中心或投资者关系邮箱提前提问，公司在说明会上将对普遍关注的问题进行回应。说明会结束后可通过上证路演中心查看会议情况。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111000034589.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2582866726","title":"每周股票复盘：成都先导（688222）股东减持185.94万股，股价上涨12.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582866726","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582866726?lang=zh_cn&edition=full","pubTime":"2025-11-09 02:15","pubTimestamp":1762625716,"startTime":"0","endTime":"0","summary":"截至2025年11月7日收盘，成都先导报收于23.23元，较上周的25.23元下跌7.93%。减持期间公司股价上涨12.96%，截至11月3日收盘报25.19元。答：成都先导的超1.2万亿小分子化合物库是全球目前已知规模最大、化合物最多的实体小分子化合物库。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110900000413.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2581009061","title":"11月7日成都先导发布公告，股东减持185.94万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581009061","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581009061?lang=zh_cn&edition=full","pubTime":"2025-11-07 19:01","pubTimestamp":1762513302,"startTime":"0","endTime":"0","summary":"证券之星消息，11月7日成都先导发布公告《成都先导:成都先导药物开发股份有限公司股东深圳市钧天投资企业(有限合伙)减持股份结果公告》，其股东深圳市钧天投资企业(有限合伙)于2025年8月28日至2025年11月3日间合计减持185.94万股，占公司目前总股本的0.4641%，变动期间该股股价上涨12.96%，截止11月3日收盘报25.19元。股东增减持详情见下表：根据成都先导2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110700032151.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688222"],"gpt_icon":0},{"id":"2580223746","title":"【机构调研记录】红塔红土调研成都先导","url":"https://stock-news.laohu8.com/highlight/detail?id=2580223746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580223746?lang=zh_cn&edition=full","pubTime":"2025-11-03 08:04","pubTimestamp":1762128240,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月31日披露的机构调研信息，红塔红土近期对1家上市公司进行了调研，相关名单如下：1）成都先导 调研纪要：药物发现前端持续创新，客户对新分子和多样化靶点需求上升。旗下最近一年表现最佳的公募基金产品为红塔红土信息产业精选股票发起式A，最新单位净值为2.07，近一年增长68.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110300001982.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2580475673","title":"每周股票复盘：成都先导（688222）Q3净利增114.98%","url":"https://stock-news.laohu8.com/highlight/detail?id=2580475673","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580475673?lang=zh_cn&edition=full","pubTime":"2025-11-02 02:56","pubTimestamp":1762023370,"startTime":"0","endTime":"0","summary":"截至2025年10月31日收盘，成都先导报收于25.23元，较上周的23.34元上涨8.1%。本周，成都先导10月31日盘中最高价报25.49元。股本股东变化截至2025年9月30日，成都先导股东户数为2.07万户，较6月30日增加2488户，增幅13.63%。业绩披露要点2025年前三季度，成都先导实现主营收入3.7亿元，同比增长23.98%；归母净利润9287.22万元，同比增长208.34%；扣非净利润9007.38万元，同比增长420.3%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110200000488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2579920765","title":"成都先导(688222)9月30日股东户数2.07万户，较上期增加13.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579920765","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579920765?lang=zh_cn&edition=full","pubTime":"2025-10-29 17:21","pubTimestamp":1761729715,"startTime":"0","endTime":"0","summary":"证券之星消息，近日成都先导披露，截至2025年9月30日公司股东户数为2.07万户，较6月30日增加2488.0户，增幅为13.63%。在医疗服务行业个股中，成都先导股东户数低于行业平均水平，截至9月30日，医疗服务行业平均股东户数为4.67万户。从股价来看，2025年6月30日至2025年9月30日，成都先导区间涨幅为53.42%，在此期间股东户数增加2488.0户，增幅为13.63%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102900035633.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2567148273","title":"成都先导：选举第三届董事会职工代表董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2567148273","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567148273?lang=zh_cn&edition=full","pubTime":"2025-09-15 22:16","pubTimestamp":1757945760,"startTime":"0","endTime":"0","summary":"证券日报网讯 9月15日晚间，成都先导发布公告称，公司于2025年9月5日召开职工代表大会，经民主讨论、表决通过，选举瞿庆喜先生为公司第三届董事会职工代表董事。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-15/doc-infqqyue1355674.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-09-15/doc-infqqyue1355674.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688222","BK0216"],"gpt_icon":0},{"id":"1137180932","title":"成都先导合作伙伴Bioage Labs启动新型脑渗透性Nlrp3抑制剂Bge-102的1期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1137180932","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137180932?lang=zh_cn&edition=full","pubTime":"2025-09-15 21:31","pubTimestamp":1757943087,"startTime":"0","endTime":"0","summary":"成都先导合作伙伴Bioage Labs启动新型脑渗透性Nlrp3抑制剂Bge-102的1期临床试验","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688222","BK0216"],"gpt_icon":0},{"id":"2567169821","title":"成都先导：合作伙伴BioAge启动新颖NLRP3抑制剂BGE-102的I期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2567169821","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567169821?lang=zh_cn&edition=full","pubTime":"2025-09-15 09:14","pubTimestamp":1757898859,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["DEL.AU","BK7060","BK0216","BK4139","BK4109","BK4121","688222","DNA"],"gpt_icon":0},{"id":"2567135603","title":"每周股票复盘：成都先导（688222）2025年限制性股票激励对象公示无异议","url":"https://stock-news.laohu8.com/highlight/detail?id=2567135603","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567135603?lang=zh_cn&edition=full","pubTime":"2025-09-14 03:40","pubTimestamp":1757792424,"startTime":"0","endTime":"0","summary":"截至2025年9月12日收盘，成都先导报收于26.86元，较上周的27.06元下跌0.74%。公司于2025年8月28日至9月6日通过邮件系统公示拟激励对象的姓名和职务，公示期间未收到异议。成都先导药物开发股份有限公司监事会亦对拟激励对象名单发表了核查意见。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091400000777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688222"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1767897742831,"stockEarnings":[{"period":"1week","weight":0.3113},{"period":"1month","weight":0.2855},{"period":"3month","weight":0.303},{"period":"6month","weight":0.7775},{"period":"1year","weight":1.6155},{"period":"ytd","weight":0.3113}],"compareEarnings":[{"period":"1week","weight":0.0288},{"period":"1month","weight":0.0444},{"period":"3month","weight":0.0477},{"period":"6month","weight":0.1632},{"period":"1year","weight":0.264},{"period":"ytd","weight":0.0288}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都先导药物开发股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"20747人(较上一季度增加13.63%)","perCapita":"19312股","listingDate":"2020-04-16","address":"四川省成都市武侯区高新区科园南路88号1栋3层","registeredCapital":"40068万元","survey":" 成都先导药物开发股份有限公司的主营业务是DEL技术相关的药物研发服务。公司的主要产品是小分子及核酸新药。","listedPrice":20.52},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"成都先导(688222)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供成都先导(688222)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"成都先导,688222,成都先导股票,成都先导股票老虎,成都先导股票老虎国际,成都先导行情,成都先导股票行情,成都先导股价,成都先导股市,成都先导股票价格,成都先导股票交易,成都先导股票购买,成都先导股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"成都先导(688222)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供成都先导(688222)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}